The Genotyping Assay Market is
projected to reach USD 31.9 billion by 2023 from USD 11.8 billion in 2018, at a
CAGR of 22.0%. This study involved the extensive use of both primary and
secondary sources.
The research process involved the study of various factors
affecting the industry to identify the segmentation types, industry trends, key
players, competitive landscape, key market dynamics, and key player strategies.
Genotyping Assay
Market segmentation:
·
Based on product
·
Based on technology
·
Based on Application
·
Based on End User
·
Based on Region
To know about the
assumptions considered for the study download the pdf brochure, Here: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595
The Major Players Operating
in the Genotyping Assay Market:
The prominent players in the genotyping assay market are Thermo
Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent
Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland),
GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins
Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of
California (US), GENEWIZ (US), and Integrated DNA Technologies (US).
Illumina (US), Thermo Fisher Scientific (US), QIAGEN
(Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche
Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US),
PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US),
Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA
Technologies (US) are some key players in this market. These companies are
focusing on increasing their presence in the high-growth markets through both
organic as well as inorganic growth strategies such as product launches,
approvals & enhancements; expansion; agreements, collaboration & partnerships;
and acquisition.
Geographical Detailed
Analysis for Genotyping Assay Market:
North America is expected to account for the largest share
of the genotyping assay market in 2018, followed by Europe and the Asia
Pacific. The increasing adoption of technologically advanced genotyping
products, the high
healthcare expenditure, presence of advanced healthcare infrastructure,
highly developed healthcare systems in the US and Canada, large number of
genotyping-based R&D projects, and the presence of a large number of
leading genotyping manufacturers in the region, along with an increasing demand
from pharmaceutical companies for genotyping products and rising investments by
government bodies, are responsible for the large share of the North American
genotyping market.
No comments:
Post a Comment